Base de dados : MEDLINE
Pesquisa : B03.510.024.049.525.500.720.400 [Categoria DeCS]
Referências encontradas : 415 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 42 ir para página                         

  1 / 415 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384899
[Au] Autor:Zhang J; Huang X; Zhang X; Zhu Y; Liao K; Ma J; Wang G; Guo Y; Xie C
[Ad] Endereço:Department of Respiratory Medicine.
[Ti] Título:Coinfection of disseminated Talaromyces marneffei and Mycobacteria kansasii in a patient with papillary thyroid cancer: A case report.
[So] Source:Medicine (Baltimore);96(52):e9072, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Recently, Talaromyces marneffei (T. marneffei) has been reported in human immunodeficiency virus (HIV)-negative patient with underlying diseases, such as oral cancer, colon cancer, haematological malignancies, connective tissue disease, diabetes mellitus, and corticosteroids or immunosuppressive agents. Similar to HIV-positive ones, such patients were observed with CD4 lymphocytopenia. PATIENT CONCERNS: We reported a case of a 45-year-old woman who was diagnosed with disseminated T. marneffei and Mycobacteria kansasii (M. kansasii) with papillary thyroid cancer as the underlying disease. T-cell subsets counts, CD4 T-cell%, CD8 T-cell%, CD4/CD8 ratio, and NK cell% were all turned out to be normal. DIAGNOSES: Based on bronchoalveolar lavage fluid and skin lesions secretion cultures, blood culture, the patient was diagnosed with disseminated T. marneffei and M. kansasii. Pathological examination reported papillary thyroid cancer with cervical lymph node metastasis. INTERVENTIONS: The patient received the combined and longer antifungal therapy and drug regimens for M. kansasii. She had total thyroidectomy with radical neck dissection to treat the papillary thyroid cancer. OUTCOMES: The patient had a favorable outcome for 19 months without recurrence. LESSONS: T. marneffei could infect non-HIV individuals with underlying disease under the condition of normal T-cell counts. The symptoms were lack of specificity and were more likely to be misdiagnosed. Such patients with unidentified T-cell dysfunction or other unidentified primary immunodeficiency disorders may prone to coinfect with other opportunistic pathogens, such as M. kansasii. Compared with HIV-positive ones, they need combined and much longer antifungal therapy.
[Mh] Termos MeSH primário: Carcinoma Papilar/microbiologia
Coinfecção
Infecções por Micobactéria não Tuberculosa/complicações
Mycobacterium kansasii
Micoses/complicações
Talaromyces
Neoplasias da Glândula Tireoide/microbiologia
[Mh] Termos MeSH secundário: Antibacterianos/uso terapêutico
Antifúngicos/uso terapêutico
Carcinoma Papilar/patologia
Carcinoma Papilar/terapia
Feminino
Seres Humanos
Meia-Idade
Infecções por Micobactéria não Tuberculosa/diagnóstico
Infecções por Micobactéria não Tuberculosa/terapia
Micoses/diagnóstico
Micoses/terapia
Esvaziamento Cervical
Neoplasias da Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/terapia
Tireoidectomia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antifungal Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009072


  2 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28629501
[Au] Autor:Shahraki AH; Trovato A; Mirsaeidi M; Borroni E; Heidarieh P; Hashemzadeh M; Shahbazi N; Cirillo DM; Tortoli E
[Ad] Endereço:1​Department of Epidemiology, Pasteur Institute of Iran, Tehran, Iran.
[Ti] Título:Mycobacterium persicum sp. nov., a novel species closely related to Mycobacterium kansasii and Mycobacterium gastri.
[So] Source:Int J Syst Evol Microbiol;67(6):1766-1770, 2017 Jun.
[Is] ISSN:1466-5034
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Four strains isolated in Iran from pulmonary specimens of unrelated patients are proposed as representative of a novel Mycobacterium species. Similarity, at the phenotypic level, with Mycobacterium kansasii is remarkable with the photochromogenic yellow pigmentation of the colonies being the salient feature. They differ, however, genotypically from this species and present unique sequences in 16S rRNA, hsp65 and rpoB genes. The average nucleotide identity and the genome-to-genome distance fully support the status of an independent species. The name proposed for this species is Mycobacterium persicum sp. nov. with AFPC-000227T (=DSM 104278T=CIP 111197T) as the type strain.
[Mh] Termos MeSH primário: Pulmão/microbiologia
Mycobacterium/classificação
Filogenia
[Mh] Termos MeSH secundário: Técnicas de Tipagem Bacteriana
DNA Bacteriano/genética
Feminino
Genes Bacterianos
Seres Humanos
Irã (Geográfico)
Masculino
Meia-Idade
Mycobacterium/genética
Mycobacterium/isolamento & purificação
Mycobacterium kansasii
Pigmentação
RNA Ribossômico 16S/genética
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Bacterial); 0 (RNA, Ribosomal, 16S)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE
[do] DOI:10.1099/ijsem.0.001862


  3 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28317629
[Au] Autor:Saleem N; Saba R; Maddika S; Weinstein M
[Ad] Endereço:Infectious Diseases Section, Department of Internal Medicine, Presence Saint Joseph Hospital, Chicago, Illinois. Electronic address: nasirsaleemmd@gmail.com.
[Ti] Título:Mycobacterium kansasii Infection in a Patient Receiving Biologic Therapy-Not All Reactive Interferon Gamma Release Assays Are Tuberculosis.
[So] Source:Am J Med Sci;353(4):394-397, 2017 Apr.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mycobacterium kansasii, a nontuberculous mycobacterium, can lead to lung disease similar to tuberculosis. Immunotherapeutic biologic agents predispose to infections with mycobacteria, including M kansasii. T-cell-mediated interferon gamma release assays like QuantiFERON-TB Gold Test (QFT) are widely used by clinicians for the diagnosis of infections with Mycobacterium tuberculosis; however, QFT may also show positive result with certain nontuberculous mycobacterial infections. We report a case of M kansasii pulmonary infection, with a positive QFT, in an immunocompromised patient receiving prednisone, leflunomide and tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody. This case highlights the risk of mycobacterial infections with the use of various biologic agents and the need for caution when interpreting the results of interferon gamma release assays.
[Mh] Termos MeSH primário: Infecções por Micobactéria não Tuberculosa/diagnóstico
Mycobacterium kansasii/isolamento & purificação
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Hospedeiro Imunocomprometido
Meia-Idade
Infecções por Micobactéria não Tuberculosa/complicações
Infecções por Micobactéria não Tuberculosa/microbiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE


  4 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28297817
[Au] Autor:Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
[Ad] Endereço:Central Laboratory of Beijing Research Institute for Tuberculosis Control, Beijing 100035, China.
[Ti] Título:[Distribution and drug resistance of nontuberculous in Beijing].
[So] Source:Zhonghua Jie He He Hu Xi Za Zhi;40(3):210-214, 2017 Mar 12.
[Is] ISSN:1001-0939
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To analyze the distribution and drug resistance of nontuberculous mycobacteria(NTM) in Beijing. Using PCR-fluorescence probe method we identified 1 552 mycobacterial isolates in 2009 and 1 553 mycobacterial isolates in 2013, which were stored by Beijing Research Institute for Tuberculosis Control.All identified NTM strains were confirmed by 16S rRNA gene sequencing, and drug sensitivity testing was performed by using 1% ratio method.SPSS 13.0 was used for statistical analysis. The isolation rate for NTM in 2009 and 2013 was 3.8%(59/1 552), and 4.6%(71/1 553) respectively. A total of 130 NTM strains were identified to 13 species by 16S rRNA gene sequencing, including . strains 39.2%(51/130), . strains 37.7%(49/130), . strains 6.9%(9/130), . strains 5.4%(7/130), . strains 3.0%(4/130), . strains 1.5%(2/130), . strains 1.5%(2/130), . . . . . . 1 strain each. For the patients infected with NTM, 87 were male and 43 were female, with an average age of 55 years. The results of drug sensitivity test from 97 strains of NTM showed that isoniazid and p-aminosalicylic acid showed the highest drug resistant rate of 98%(95/97), followed by streptomycin 94.8%(92/97), capreomycin 81.4%(79/97), amikacin 69.1%(67/97), levofloxacin 56.7%(55/97), rifampicin 54.6%(53/97), prothionamide 51.5%(50/97), and ethambutol 50.5%(49/97). and were the main strains isolated from patients infected with NTM in Beijing. Patients infected with NTM were mostly males. NTM showed high resistance to anti-tuberculosis drugs.
[Mh] Termos MeSH primário: Antibióticos Antituberculose/farmacologia
Infecções por Micobactéria não Tuberculosa/diagnóstico
Infecções por Micobactéria não Tuberculosa/tratamento farmacológico
Micobactérias não Tuberculosas/efeitos dos fármacos
Micobactérias não Tuberculosas/isolamento & purificação
[Mh] Termos MeSH secundário: Pequim/epidemiologia
Etambutol/farmacologia
Feminino
Seres Humanos
Isoniazida/farmacologia
Masculino
Testes de Sensibilidade Microbiana
Infecções por Micobactéria não Tuberculosa/epidemiologia
Complexo Mycobacterium avium/genética
Complexo Mycobacterium avium/isolamento & purificação
Mycobacterium kansasii/genética
Mycobacterium kansasii/isolamento & purificação
Micobactérias não Tuberculosas/classificação
Micobactérias não Tuberculosas/genética
Reação em Cadeia da Polimerase
RNA Ribossômico 16S/genética
Rifampina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antitubercular); 0 (RNA, Ribosomal, 16S); 8G167061QZ (Ethambutol); V83O1VOZ8L (Isoniazid); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1001-0939.2017.03.013


  5 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28185617
[Au] Autor:Johnston JC; Chiang L; Elwood K
[Ad] Endereço:Division of Tuberculosis Control, British Columbia Centre for Disease Control, Vancouver, British Columbia V5Z 4R4, Canada.
[Ti] Título:Mycobacterium kansasii.
[So] Source:Microbiol Spectr;5(1), 2017 Jan.
[Is] ISSN:2165-0497
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The incidence of Mycobacterium kansasii varies widely over time and by region, but this organism remains one of the most clinically relevant isolated species of nontuberculous mycobacteria. In contrast to other common nontuberculous mycobacteria, M. kansasii is infrequently isolated from natural water sources or soil. The major reservoir appears to be tap water. Infection is likely acquired through the aerosol route, with low infectivity in regions of endemicity. Human-to-human transmission is thought not to occur. Clinical syndromes and radiological findings of M. kansasii infection are mostly indistinguishable from that of Mycobacterium tuberculosis, thus requiring microbiological confirmation. Disseminated disease is uncommon in HIV-negative patients and usually associated with severe immunosuppression. The majority of patients with M. kansasii pulmonary disease have underlying pulmonary comorbidities, such as smoking, chronic obstructive pulmonary disease, bronchiectasis, and prior or concurrent M. tuberculosis infection. Surveys in Great Britain, however, noted higher rates, with 8 to 9% of M. kansasii infections presenting with extrapulmonary disease. Common sites of extrapulmonary disease include the lymph nodes, skin, and musculoskeletal and genitourinary systems. The specificity of gamma interferon release assays (IGRAs) for M. tuberculosis may be reduced by M. kansasii infection, as M. kansasii encodes CFP-10 and ESAT-6, two antigens targeted by IGRAs. A study conducted to evaluate the therapy in rifampin-resistant disease found that patients with acquired rifampin resistance were treated with daily high-dose ethambutol, isoniazid, sulfamethoxazole, and pyridoxine combined with aminoglycoside therapy. Given the potential toxicities, particularly with aminoglycoside therapy, clarithromycin and/or moxifloxacin therapy could be considered as alternatives.
[Mh] Termos MeSH primário: Antituberculosos/uso terapêutico
Exposição Ambiental
Infecções por Micobactéria não Tuberculosa/epidemiologia
Infecções por Micobactéria não Tuberculosa/microbiologia
Mycobacterium kansasii/isolamento & purificação
Microbiologia da Água
[Mh] Termos MeSH secundário: Saúde Global
Seres Humanos
Infecções por Micobactéria não Tuberculosa/diagnóstico
Infecções por Micobactéria não Tuberculosa/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antitubercular Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1128/microbiolspec.TNMI7-0011-2016


  6 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28001372
[Au] Autor:Sherlock ME; Breaker RR
[Ad] Endereço:Department of Molecular Biophysics and Biochemistry, ‡Department of Molecular, Cellular, and Developmental Biology, and §Howard Hughes Medical Institute, Yale University , New Haven, Connecticut 06520, United States.
[Ti] Título:Biochemical Validation of a Third Guanidine Riboswitch Class in Bacteria.
[So] Source:Biochemistry;56(2):359-363, 2017 Jan 17.
[Is] ISSN:1520-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recently, it was determined that representatives of the riboswitch candidates called ykkC and mini-ykkC directly bind free guanidine. These riboswitches regulate the expression of genes whose protein products are implicated in overcoming the toxic effects of this ligand. Thus, the relevant ykkC motif and mini-ykkC motif RNAs have been classified as guanidine-I and guanidine-II riboswitch RNAs, respectively. Moreover, we had previously noted that a third candidate riboswitch class, called ykkC-III, was associated with a distribution of genes similar to those of the other two motifs. Therefore, it was predicted that ykkC-III motif RNAs would sense and respond to the same ligand. In this report, we present biochemical data supporting the hypothesis that ykkC-III RNAs represent a third class of guanidine-sensing RNAs called guanidine-III riboswitches. Members of the guanidine-III riboswitch class bind their ligand with an affinity similar to that observed for members of the other two classes. Notably, there are some sequence similarities between guanidine-II and guanidine-III riboswitches. However, the characteristics of ligand discrimination by guanidine-III RNAs are different from those of the other guanidine-binding motifs, suggesting that the binding pockets have distinct features among the three riboswitch classes.
[Mh] Termos MeSH primário: Regulação Bacteriana da Expressão Gênica
Genes Bacterianos
Guanidinas/farmacologia
Nocardia/efeitos dos fármacos
RNA Bacteriano/química
Riboswitch
[Mh] Termos MeSH secundário: Aptâmeros de Nucleotídeos/genética
Aptâmeros de Nucleotídeos/metabolismo
Biologia Computacional
Guanidinas/metabolismo
Legionella pneumophila/efeitos dos fármacos
Legionella pneumophila/genética
Legionella pneumophila/metabolismo
Ligantes
Mycobacterium kansasii/efeitos dos fármacos
Mycobacterium kansasii/genética
Mycobacterium kansasii/metabolismo
Nocardia/genética
Nocardia/metabolismo
Conformação de Ácido Nucleico
RNA Bacteriano/genética
RNA Bacteriano/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Aptamers, Nucleotide); 0 (Guanidines); 0 (Ligands); 0 (RNA, Bacterial); 0 (Riboswitch)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1021/acs.biochem.6b01271


  7 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27934834
[Au] Autor:Padmapriyadarsini C; Nair D; Gomathi NS; Velayudham B
[Ad] Endereço:Department of Clinical Research, National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.
[Ti] Título:Pulmonary disease in immunocompetent host: Treatment outcomes with short-course chemotherapy.
[So] Source:Indian J Med Microbiol;34(4):516-519, 2016 Oct-Dec.
[Is] ISSN:1998-3646
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Mycobacterium kansasii, most virulent of all atypical mycobacteria, causes pulmonary disease identical to the disease caused by Mycobacterium tuberculosis. Early identification of the species and prompt initiation of treatment for M. kansasii is necessary to prevent morbidity and mortality due to this disease. This case series highlights the similarity in the clinical presentation of both M. tuberculosis and M. kansasii and response to direct observation of short-course chemotherapy with rifampicin, in the management of pulmonary M. kansasii disease. Larger studies are required to evaluate the long-term effect of short-course chemotherapy, especially use of moxifloxacin, in the management of pulmonary M. kansasii disease.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Infecções por Micobactéria não Tuberculosa/tratamento farmacológico
Infecções por Micobactéria não Tuberculosa/microbiologia
Mycobacterium kansasii/isolamento & purificação
Pneumonia Bacteriana/tratamento farmacológico
Pneumonia Bacteriana/microbiologia
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Fluoroquinolonas/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Infecções por Micobactéria não Tuberculosa/patologia
Pneumonia Bacteriana/patologia
Rifampina/uso terapêutico
Resultado do Tratamento
Tuberculose Pulmonar/microbiologia
Tuberculose Pulmonar/patologia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoroquinolones); U188XYD42P (moxifloxacin); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161210
[St] Status:MEDLINE
[do] DOI:10.4103/0255-0857.195370


  8 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27911922
[Au] Autor:Jiang F; Huang W; Wang Y; Tian P; Chen X; Liang Z
[Ad] Endereço:Department of Respiratory and Critical Care Medicine, West China Medical School and West China Hospital, Sichuan University, Chengdu, Sichuan, China.
[Ti] Título:Nucleic Acid Amplification Testing and Sequencing Combined with Acid-Fast Staining in Needle Biopsy Lung Tissues for the Diagnosis of Smear-Negative Pulmonary Tuberculosis.
[So] Source:PLoS One;11(12):e0167342, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Smear-negative pulmonary tuberculosis (PTB) is common and difficult to diagnose. In this study, we investigated the diagnostic value of nucleic acid amplification testing and sequencing combined with acid-fast bacteria (AFB) staining of needle biopsy lung tissues for patients with suspected smear-negative PTB. METHODS: Patients with suspected smear-negative PTB who underwent percutaneous transthoracic needle biopsy between May 1, 2012, and June 30, 2015, were enrolled in this retrospective study. Patients with AFB in sputum smears were excluded. All lung biopsy specimens were fixed in formalin, embedded in paraffin, and subjected to acid-fast staining and tuberculous polymerase chain reaction (TB-PCR). For patients with positive AFB and negative TB-PCR results in lung tissues, probe assays and 16S rRNA sequencing were used for identification of nontuberculous mycobacteria (NTM). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of PCR and AFB staining were calculated separately and in combination. RESULTS: Among the 220 eligible patients, 133 were diagnosed with TB (men/women: 76/57; age range: 17-80 years, confirmed TB: 9, probable TB: 124). Forty-eight patients who were diagnosed with other specific diseases were assigned as negative controls, and 39 patients with indeterminate final diagnosis were excluded from statistical analysis. The sensitivity, specificity, PPV, NPV, and accuracy of histological AFB (HAFB) for the diagnosis of smear-negative were 61.7% (82/133), 100% (48/48), 100% (82/82), 48.5% (48/181), and 71.8% (130/181), respectively. The sensitivity, specificity, PPV, and NPV of histological PCR were 89.5% (119/133), 95.8% (46/48), 98.3% (119/121), and 76.7% (46/60), respectively, demonstrating that histological PCR had significantly higher accuracy (91.2% [165/181]) than histological acid-fast staining (71.8% [130/181]), P < 0.001. Parallel testing of histological AFB staining and PCR showed the sensitivity, specificity, PPV, NPV, and accuracy to be 94.0% (125/133), 95.8% (46/48), 98.4% (125/127), 85.2% (46/54), and 94.5% (171/181), respectively. Among patients with positive AFB and negative PCR results in lung tissue specimens, two were diagnosed with NTM infections (Mycobacterium avium-intracellulare complex and Mycobacterium kansasii). CONCLUSION: Nucleic acid amplification testing combined with acid-fast staining in lung biopsy tissues can lead to early and accurate diagnosis in patients with smear-negative pulmonary tuberculosis. For patients with positive histological AFB and negative tuberculous PCR results in lung tissue, NTM infection should be suspected and could be identified by specific probe assays or 16S rRNA sequencing.
[Mh] Termos MeSH primário: Mycobacterium tuberculosis/genética
Reação em Cadeia da Polimerase/métodos
RNA Bacteriano/genética
RNA Ribossômico 16S/genética
Coloração e Rotulagem/métodos
Tuberculose Pulmonar
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Biópsia por Agulha Fina
Feminino
Seres Humanos
Pulmão/microbiologia
Pulmão/patologia
Masculino
Meia-Idade
Mycobacterium kansasii/genética
Tuberculose Pulmonar/genética
Tuberculose Pulmonar/microbiologia
Tuberculose Pulmonar/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Bacterial); 0 (RNA, Ribosomal, 16S)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161203
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0167342


  9 / 415 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27537867
[Au] Autor:Gonec T; Pospisilova S; Kauerova T; Kos J; Dohanosova J; Oravec M; Kollar P; Coffey A; Liptaj T; Cizek A; Jampilek J
[Ad] Endereço:Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho 1, Brno 61242, Czech Republic. t.gonec@seznam.cz.
[Ti] Título:N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity.
[So] Source:Molecules;21(8), 2016 Aug 16.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:A series of nineteen N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides and a series of their nineteen positional isomers N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides were prepared and characterized. Primary in vitro screening of all the synthesized compounds was performed against Mycobacterium tuberculosis H37Ra, M. kansasii and M. smegmatis. Screening of the cytotoxicity of the compounds was performed using human monocytic leukemia THP-1 cells. Some of the tested compounds showed antimycobacterial activity comparable with or higher than that of rifampicin. For example, 2-hydroxy-N-(4-propoxyphenyl)-naphthalene-1-carboxamide showed the highest activity (MIC = 12 µM) against M. tuberculosis with insignificant cytotoxicity. N-[3-(But-2-yloxy)phenyl]- and N-[4-(but-2-yloxy)phenyl]-2-hydroxy-naphthalene-1-carboxamide demonstrated high activity against all tested mycobacterial strains and insignificant cytotoxicity. N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides demonstrated rather high effect against M. smegmatis and M. kansasii and strong antiproliferative effect against the human THP-1 cell line. Lipophilicity was found as the main physicochemical parameter influencing the activity. A significant decrease of mycobacterial cell metabolism (viability of M. tuberculosis H37Ra) was observed using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) assay. Structure-activity relationships are discussed.
[Mh] Termos MeSH primário: Antibacterianos/síntese química
Antibacterianos/farmacologia
Viabilidade Microbiana/efeitos dos fármacos
Naftóis/síntese química
Naftóis/farmacologia
[Mh] Termos MeSH secundário: Antibacterianos/química
Linhagem Celular
Proliferação Celular/efeitos dos fármacos
Seres Humanos
Testes de Sensibilidade Microbiana
Estrutura Molecular
Mycobacterium kansasii/efeitos dos fármacos
Mycobacterium smegmatis/efeitos dos fármacos
Mycobacterium tuberculosis/efeitos dos fármacos
Naftóis/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Naphthols)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160819
[St] Status:MEDLINE


  10 / 415 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27207809
[Au] Autor:Wassilew N; Hoffmann H; Andrejak C; Lange C
[Ad] Endereço:Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
[Ti] Título:Pulmonary Disease Caused by Non-Tuberculous Mycobacteria.
[So] Source:Respiration;91(5):386-402, 2016.
[Is] ISSN:1423-0356
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease.
[Mh] Termos MeSH primário: Infecções por Micobactéria não Tuberculosa/epidemiologia
Micobactérias não Tuberculosas
Tuberculose Pulmonar/epidemiologia
[Mh] Termos MeSH secundário: Europa (Continente)/epidemiologia
Seres Humanos
Pulmão/diagnóstico por imagem
Infecções por Micobactéria não Tuberculosa/diagnóstico
Infecções por Micobactéria não Tuberculosa/tratamento farmacológico
Infecções por Micobactéria não Tuberculosa/microbiologia
Complexo Mycobacterium avium
Infecção por Mycobacterium avium-intracellulare/diagnóstico
Infecção por Mycobacterium avium-intracellulare/tratamento farmacológico
Infecção por Mycobacterium avium-intracellulare/epidemiologia
Mycobacterium kansasii
Mycobacterium xenopi
Tomografia Computadorizada por Raios X
Tuberculose Pulmonar/diagnóstico
Tuberculose Pulmonar/tratamento farmacológico
Tuberculose Pulmonar/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160522
[St] Status:MEDLINE
[do] DOI:10.1159/000445906



página 1 de 42 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde